Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Rotow, Julia K.
Costa, Daniel Botelho
Paweletz, Cloud P.
Awad, Mark M.
Marcoux, Paul
Rangachari, Deepa
Barbie, David Allen
Sands, Jacob
Cheng, Michael L.
Johnson, Bruce E.
Oxnard, Geoffrey R.
Jackman, David Michael
Kwiatkowski, David J.
Kehl, Kenneth L.
Izdebski, Monika D.
Lau, Christie J.
Vasquez, Kevin A.
Janne, Pasi A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9507
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [2] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [3] Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer
    Chen, H.
    Lin, M.
    Jiang, J.
    Liu, M.
    Lai, Z.
    Luo, Y.
    Ye, H.
    Chen, H.
    Yang, Z.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S55 - S55
  • [4] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
    Hori, Tomoki
    Yamamoto, Kazuhiro
    Ito, Takefumi
    Ikushima, Shigeki
    Omura, Tomohiro
    Yano, Ikuko
    [J]. INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
  • [5] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    [J]. JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [6] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    Chmielecki, Juliann
    Gray, Jhanelle E.
    Cheng, Ying
    Ohe, Yuichiro
    Imamura, Fumio
    Cho, Byoung Chul
    Lin, Meng-Chih
    Majem, Margarita
    Shah, Riyaz
    Rukazenkov, Yuri
    Todd, Alexander
    Markovets, Aleksandra
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Ramalingam, Suresh S.
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [7] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [8] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [9] Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
    Lu, S.
    Cho, B. C.
    Lee, J-S.
    Lee, S-H.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Xiong, H.
    How, S. H.
    Chang, G-C.
    Yang, J. C-H.
    Yoshioka, H.
    Xia, K.
    Martinez, M.
    Bauml, J. M.
    Sethi, S.
    Hayashi, H.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1661
  • [10] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
    Huang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S431 - S432
12345